Guizhou Xinbang Pharmaceutical Co., Ltd.

XSEC:002390 Stock Report

Market Cap: CN¥8.6b

Guizhou Xinbang Pharmaceutical Past Earnings Performance

Past criteria checks 2/6

Guizhou Xinbang Pharmaceutical has been growing earnings at an average annual rate of 32.8%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 0.4% per year. Guizhou Xinbang Pharmaceutical's return on equity is 4%, and it has net margins of 3.5%.

Key information

32.8%

Earnings growth rate

30.4%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate0.4%
Return on equity4.0%
Net Margin3.5%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Guizhou Xinbang Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSEC:002390 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 246,2032177666
30 Jun 246,2512467645
31 Mar 246,4382937845
31 Dec 236,4612878035
30 Sep 236,4872308163
30 Jun 236,4632498263
31 Mar 236,3772048592
01 Jan 236,3502248551
30 Sep 226,4353048132
30 Jun 226,5172528271
31 Mar 226,5902748022
01 Jan 226,4722737932
30 Sep 216,2892608221
30 Jun 216,2412908062
31 Mar 216,0602597873
31 Dec 205,84617481311
30 Sep 205,91615982923
30 Jun 206,08015187230
31 Mar 206,33916193232
31 Dec 196,65523692537
30 Sep 196,573-1,36096338
30 Jun 196,584-1,37192636
31 Mar 196,630-1,30892441
31 Dec 186,580-1,29791837
30 Sep 186,65133783430
30 Jun 186,52736881547
31 Mar 186,16034173138
31 Dec 176,00231970830
30 Sep 175,80029380022
30 Jun 175,4372637920
31 Mar 175,3502557930
31 Dec 165,1572467560
30 Sep 165,0442436680
30 Jun 164,8642236240
31 Mar 164,4881855930
31 Dec 154,1801745400
30 Sep 153,7881894620
30 Jun 153,4771804400
31 Mar 153,2171724200
31 Dec 142,4761453890
30 Sep 141,7321003650
30 Jun 141,113693430
31 Mar 14572393010
31 Dec 13569403010

Quality Earnings: 002390 has high quality earnings.

Growing Profit Margin: 002390's current net profit margins (3.5%) are lower than last year (3.5%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 002390 has become profitable over the past 5 years, growing earnings by 32.8% per year.

Accelerating Growth: 002390's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 002390 had negative earnings growth (-5.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).

Return on Equity

High ROE: 002390's Return on Equity (4%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 00:05
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Guizhou Xinbang Pharmaceutical Co., Ltd. is covered by 11 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhouyu DengBOCI Research Ltd.
Songtao YEChangjiang Securities Co. LTD.
Yichi ZhangChina International Capital Corporation Limited